THE IMPACT OF LEUKEMIA STATUS AT THE TIME OF HLA‐IDENTICAL SIBLING MARROW TRANSPLANTATION ON SUBSEQUENT COMPLICATION RATE AND SURVIVAL OF ADULTS WITH ACUTE LEUKEMIA

Publisher Website
Google Scholar
Abstract
Between March 1981 and March 1985, 76 patients with acute leukemia were treated with cyclophosphamide (120 mg/kg), 12 or 14 Gy total body irradiation, and an HLA‐identical sibling marrow transplant. Forty‐seven patients had acute non‐lymphoblastic leukemia (ANLL) and 29 had acute lymphoblastic leukemia (ALL). Forty‐one were transplanted during first remission and 28 during or after first relapse of their disease. An additional six patients were transplanted because their leukemia was refractory to conventional cytotoxic chemotherapy, and one was transplanted as initial therapy. Actuarial 42 month survival for those transplanted during first remission was 47% and for those transplanted in first relapse or later it was 22% (p = 0.02). There was no difference in either group between those with ANLL and those with ALL. Two of the six patients with refractory leukemia are alive more than 22 and more than 15 months after the transplant. The incidence of acute graft‐versus‐host disease and interstitial pneumonitis was 90% and 39%, respectively, for the first remission group, and 96% and 37% for those transplanted in first relapse or later. There was no significant difference in transplant‐related mortality between the two groups (29% and 43%, respectively). The leukemia recurrence rate, however, was 13% for those transplanted in first remission and 67% for those transplanted in first relapse or later (p = 0.0003). Thus, the major factor determining the incidence of leukemia recurrence and survival after transplant was the status of the leukemia at the time of transplantation. These findings indicate that adults with acute leukemia who have an HLA‐identical sibling should be transplanted in first remission, and that transplant‐related mortality must be reduced urgently. (Aust NZ J Med 1986; 16: 462–469.)